Brandes Investment Partners LP Cuts Holdings in Takeda Pharmaceutical Company Limited (NYSE:TAK)

Brandes Investment Partners LP lowered its position in Takeda Pharmaceutical Company Limited (NYSE:TAK - Free Report) by 5.9% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 3,039,585 shares of the company's stock after selling 192,019 shares during the period. Brandes Investment Partners LP owned approximately 0.10% of Takeda Pharmaceutical worth $40,244,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors have also added to or reduced their stakes in the company. Versant Capital Management Inc bought a new stake in shares of Takeda Pharmaceutical during the fourth quarter valued at approximately $26,000. Wilmington Savings Fund Society FSB bought a new stake in shares of Takeda Pharmaceutical during the third quarter valued at approximately $40,000. BNP Paribas Financial Markets raised its stake in shares of Takeda Pharmaceutical by 416.0% during the third quarter. BNP Paribas Financial Markets now owns 3,220 shares of the company's stock valued at $46,000 after acquiring an additional 2,596 shares in the last quarter. Smithfield Trust Co raised its stake in shares of Takeda Pharmaceutical by 76.9% during the third quarter. Smithfield Trust Co now owns 3,428 shares of the company's stock valued at $49,000 after acquiring an additional 1,490 shares in the last quarter. Finally, Farther Finance Advisors LLC raised its stake in shares of Takeda Pharmaceutical by 123.6% during the fourth quarter. Farther Finance Advisors LLC now owns 3,575 shares of the company's stock valued at $47,000 after acquiring an additional 1,976 shares in the last quarter. Institutional investors own 9.17% of the company's stock.

Remove Ads

Takeda Pharmaceutical Trading Down 0.3 %

Shares of Takeda Pharmaceutical stock traded down $0.05 on Wednesday, hitting $15.14. 1,139,193 shares of the company traded hands, compared to its average volume of 1,798,999. The stock's 50 day moving average price is $13.83 and its 200-day moving average price is $13.91. The company has a current ratio of 1.31, a quick ratio of 0.72 and a debt-to-equity ratio of 0.63. Takeda Pharmaceutical Company Limited has a 52 week low of $12.58 and a 52 week high of $15.24. The company has a market cap of $48.16 billion, a PE ratio of 37.84, a PEG ratio of 0.24 and a beta of 0.46.

Takeda Pharmaceutical (NYSE:TAK - Get Free Report) last posted its quarterly earnings results on Thursday, January 30th. The company reported $0.42 earnings per share for the quarter, beating the consensus estimate of $0.34 by $0.08. Takeda Pharmaceutical had a net margin of 4.53% and a return on equity of 9.39%. Equities research analysts predict that Takeda Pharmaceutical Company Limited will post 1.64 EPS for the current year.

Takeda Pharmaceutical Company Profile

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience.